CAMBRIDGE, Mass., Jan. 9 /PRNewswire/ --
EPIX Medical, Inc. (Nasdaq: EPIX), a developer of specialty pharmaceuticals
for magnetic resonance imaging (MRI), announced today that its presentation at
the JP Morgan H&Q Healthcare Conference will be the subject of a live audio
webcast by JP Morgan, and can be accessed by registering at
http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html.
Michael D. Webb, Chief Executive Officer of EPIX will present an overview
of the company and its business strategy. The presentation is scheduled to be
delivered at 1:30 P.M. PST on Wednesday, January 9, 2002 Elizabethan Room CD
of the Westin St. Francis Hotel in San Francisco.
EPIX is a specialty pharmaceutical company based in Cambridge, MA, engaged
in developing targeted contrast agents to transform the diagnosis and clinical
management of disease using MRI. The Company's principal product under
development, MS-325, is an investigational new drug designed to enhance MRI,
now in Phase III clinical trials. To receive EPIX Medical's latest news and
other corporate developments, please visit the EPIX Medical website at
http://www.epixmed.com.
This news release contains forward-looking statements based on current
expectations of the Company's management. Such statements are subject to
risks and uncertainties which could cause actual results to differ from those
projected, including risks and uncertainties related to the conduct of, and
results obtained from, our clinical trials, our dependence on corporate
collaborations, our ability to develop multiple applications for our products
and technologies, market acceptance of our products, reimbursement policies of
third-party payors with respect to our own products, competition and
technological change.
AT EPIX MEDICAL
Michael D. Webb, CEO
Sydney Barrett, Investor Relations Manager
(617) 250-6012
SOURCE EPIX Medical, Inc.
 back to top
CONTACT:
Michael D. Webb, CEO or Sydney Barrett,
Investor Relations Manager of EPIX, +1-617-250-6012
|
